Emergent BioSolutions Inc
NYSE:EBS
Emergent BioSolutions Inc
NYSE:EBS
Price:
3.89 USD
17.88%
Market Closed
Updated:
May 4, 2024
Emergent BioSolutions Inc
Revenue
|
Emergent BioSolutions Inc
Revenue Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Emergent BioSolutions Inc
NYSE:EBS
|
Revenue
$1.3B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
15%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Emergent BioSolutions Inc
Revenue Breakdown
Breakdown by Geography
Emergent BioSolutions Inc
Emergent BioSolutions Inc
Not Available
Breakdown by Segments
Emergent BioSolutions Inc
Emergent BioSolutions Inc
|
Total Revenue:
1B
USD
|
|
Product:
944.5m
USD
|
|
Commercial Product:
497.3m
USD
|
|
Service:
72.8m
USD
|
|
Contracts And Grants:
26.3m
USD
|
See Also
What is Emergent BioSolutions Inc's Revenue?
Revenue
1.3B
USD
1.3B
USD
Based on the financial report for Mar 31, 2024, Emergent BioSolutions Inc's Revenue amounts to 1.3B USD.
What is Emergent BioSolutions Inc's Revenue growth rate?
Revenue CAGR 10Y
15%
15%
Over the last year, the Revenue growth was 38%. The average annual Revenue growth rates for Emergent BioSolutions Inc have been -8% over the past three years , 10% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
